- Home
- ZGN vs CNTA Comparison
ZGN vs CNTA Comparison
Compare ZGN & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZGN
- CNTA
- Stock Information
- Founded
- ZGN 1910
- CNTA 2020
- Country
- ZGN Italy
- CNTA United Kingdom
- Employees
- ZGN N/A
- CNTA N/A
- Industry
- ZGN Apparel
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- ZGN Consumer Discretionary
- CNTA Health Care
- Exchange
- ZGN Nasdaq
- CNTA Nasdaq
- Market Cap
- ZGN 2.0B
- CNTA 1.6B
- IPO Year
- ZGN N/A
- CNTA 2021
- Fundamental
- Price
- ZGN $9.15
- CNTA $14.07
- Analyst Decision
- ZGN Buy
- CNTA Strong Buy
- Analyst Count
- ZGN 2
- CNTA 10
- Target Price
- ZGN $8.05
- CNTA $28.78
- AVG Volume (30 Days)
- ZGN 1.9M
- CNTA 1.2M
- Earning Date
- ZGN 03-27-2025
- CNTA 08-12-2025
- Dividend Yield
- ZGN 1.58%
- CNTA N/A
- EPS Growth
- ZGN N/A
- CNTA N/A
- EPS
- ZGN 0.31
- CNTA N/A
- Revenue
- ZGN $2,015,371,157.00
- CNTA $15,000,000.00
- Revenue This Year
- ZGN $0.74
- CNTA N/A
- Revenue Next Year
- ZGN $4.74
- CNTA N/A
- P/E Ratio
- ZGN $29.46
- CNTA N/A
- Revenue Growth
- ZGN 2.21
- CNTA 118.88
- 52 Week Low
- ZGN $6.05
- CNTA $8.46
- 52 Week High
- ZGN $11.69
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- ZGN 63.83
- CNTA 60.47
- Support Level
- ZGN $8.24
- CNTA $12.74
- Resistance Level
- ZGN $8.99
- CNTA $14.27
- Average True Range (ATR)
- ZGN 0.32
- CNTA 0.66
- MACD
- ZGN -0.01
- CNTA 0.12
- Stochastic Oscillator
- ZGN 86.32
- CNTA 85.57
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.